elranatamab
pfizer
['magnetismm-1', 'multiplemyeloma', 'pfizer']
at #ash22, don t miss our oral presentation on results from the ongoing phase 1 magnetismm-1 study in patients with relapsed/refractory #multiplemyeloma. read the abstract now.
Dedicated to communicating emerging science from Pfizer Oncology. Please see our community guidelines: https://t.co/MU3blmItSZ